Terminology Flashcards
“Definitive”
Treatment with plan for a cure
Terminology for someone discontinuing treatment
“coming off of treatment”
Term for real progression
“true progression”
Term for drug approved regardless of PD-L1 level
PD-L1 agnostic
What does “y” in pathologic staging denote
Treated neoadjuvantly
Poor response to treatment term
minimal treatment effect
time until treatment is started
time to treatment
patient hasn’t been started on treatment
“treatment naive”
TTFT is
Time to first treatment
Small number of cells with microdeletion on FISH referred to as…
Small clone
Terminology to describe indolent disease
“favorable biology”
Progression on chemotherapy referred to as
primary progression
Fixed duration therapy
Time limited therapy
“line agnostic”
Can you use in any lines
giving someone the same drug
Retreat
Term for concerning lymph node
Pathologic appearing
Treatment break
Chemo holiday
Trial that was funded by pharmaceutical company
“industry sponsored”
DSS
disease specific survival
late relapse
distant relapse
Local recurrence term
loco-regional recurrence
LVSI
lymphovascular space invasion
What is “clinical benefit rate” usually defined as?
Response + stable disease
Desperation oncology
self explanatory
2 primaries diagnosed at same time (developing at same time) are typically referred to as
Synchronous primaries
If it’s not de novo metastatic then it’s
Metachronous metastatic
Rate of disease progression referred to as
Disease tempo
Term for radiation therapy target
Target Volume
Asthenia meaning
weakness
Fanconi anemia inheritance
Autosomal recessive (mostly) can be x-linked
Fanconi anemia physical exam findings
thumb hypoplasia + short stature + a few others
Fanconi anemia hallmark pathophys
Chromosomal instability/fragility (leading to cell death of hepatopoietic stem cells and progressive bone marrow failure)
Fanconi anemia lab features
macrocytic anemia
Pancytopenia
Bone marrow failure by age 40
*increased risk of solid tumors
Fanconi anemia treatment
Transplant
*careful planned conditioning regimen given chromosomal instability
Dyskeratosis congenita hallmark pathophys
Telomere biology disorder
Dyskeratosis congenita classic features
- abnormal skin pigmentation
- nail dystrophy
- leukoplakia
Dyskeratosis congenita other clinical features
- pulmonary fibrosis
- cirrhosis
- malignancies
- bone marrow failure by age 30
Dyskeratosis congenita testing
telomere length testing –
Dyskeratosis congenita treatment
anabolic steroids (short term)
HSCT
Schwachman-Diamond syndrome inheritance
autosomal recessive
Schwachman-Diamond syndrome clinical features
- pancreatic insufficiency
- BM dysfunction
- neutropenia
- MDS/AML in young adults, usually males
Schwachman-Diamond mutation
SBDS
Schwachman-Diamond syndrome treatment
G-CSF (assuming no myeloid malignancy)
Allo SCT for BM issues
Diamond blackfan anemia inheritance
autosomal dominant
Diamond blackfan anemia clinical features
- infant with red cell aplasia
- increased cancer risk
Diamond blackfan anemia treatment
- steroids
- transfusions
- HSCT
Congenital dyserythropoetic anemia pathophys
ineffective erythropoeisis leading to anemia
Congenital dyserythropoetic anemia inheritance
autosomal recessive
Congenital dyserythropoetic anemia I clinical features
- childhood
- hemolytic anemia
- binucleated erythroblasts
Cyclic neutropenia treatment
G-CSF
Severe congenital neutropenia clinical features
- severe ANC in childhood + fevers and severe infections
Severe congenital neutropenia gene association
ELANE mutation
Thrombocytopenia with absent radi (TAR) clinical features
- hypomegakaryoctyic thrombocytopenia + bilateral radial aplasia (but normal thumb)
- hemorrhagic manifestations at birth
- transient (improves after infancy)
WHIM syndrome stands for
warts
hypogammaglobulinemia
infections
myelokathexis
WHIM syndrome inheritance
autosomal dominant
GATA2 deficiency inheritance
autosomal dominant
GATA2 deficiency clinical features
very high risk of MDS
How is cure typically defined?
5 year recurrence free survival
Oncotype and other molecular profiling tools referred to as
Genomic classifiers
Walsh quote for what to do with the absence of data
Absence of evidence is not the same thing as evidence of absence
Basic term for resistant disease
Subclone
“Basic science rationale for a clinical trial”
Preclinical rationale
Term for tumor arising within a pulmonary bronchus
endobronchial
Term for describing molecular profile of a tumor
Mutational status
Remission
Synonymous with partial or complete response
Median time to response in solid tumors
6-8 weeks
PET response terminology
partial or complete metabolic response
Term for chemotherapy that increases risk for hematologic malignancy
Leukemogenic
Using a drug that is not currently approved is referred to as
Off-label use
Term to use for something that is positive on PET
PET avid
What does myeloablative chemotherapy refer to?
High dose chemotherapy, ie conditioning regimens before transplant to wipe out marrow
Using imaging to alter treatment midway through
Response adapted therapy
